AgnistaBio Inc.
AgnistaBio provides AI-driven tools to speed up drug discovery and translational research. Its AgnistaAI platforms (AgTa-Pro for protein interactions and AgTa-Ab for antibody design) use machine learning and 4D protein structure prediction to identify target proteins and develop highly developable antibodies, including GPCRs and cryptic epitopes. The approach enables high-throughput screening, early safety profiling, and rapid prototyping of molecules. The company focuses on licensing and co-development with pharma and biotech partners to address diseases with unmet medical needs such as immune diseases, cancer, and heart failure.
AgnistaBio Inc.
AgnistaBio provides AI-driven tools to speed up drug discovery and translational research. Its AgnistaAI platforms (AgTa-Pro for protein interactions and AgTa-Ab for antibody design) use machine learning and 4D protein structure prediction to identify target proteins and develop highly developable antibodies, including GPCRs and cryptic epitopes. The approach enables high-throughput screening, early safety profiling, and rapid prototyping of molecules. The company focuses on licensing and co-development with pharma and biotech partners to address diseases with unmet medical needs such as immune diseases, cancer, and heart failure.